Literature DB >> 35059976

From Initiation to Maintenance: HIV-1 Gp120-induced Neuropathic Pain Exhibits Different Molecular Mechanisms in the Mouse Spinal Cord Via Bioinformatics Analysis Based on RNA Sequencing.

Jian Huang1, Fei Lin1, Yanling Hu1, Chris Bloe Bloe1, Dan Wang1, Wenping Zhang2.   

Abstract

Human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS), remains one of the most diverse crucial health and development challenges around the world. People infected with HIV constitute a large patient population, and a significant number of them experience neuropathic pain. To study the key mechanisms that mediate HIV-induced neuropathic pain (HNP), we established an HNP mouse model via intrathecal injection of the HIV-1 envelope glycoprotein gp120. The L3~L5 spinal cord was isolated on postoperative days 1/12 (POD1/12), 1 (POD1), and 14 (POD14) for RNA sequencing to investigate the gene expression profiles of the initiation, transition, and maintenance stages of HNP. A total of 1682, 430, and 413 differentially expressed genes were obtained in POD1/12, POD1, and POD14, respectively, and their similarity was low. Bioinformatics analysis confirmed that POD1/12, POD1, and POD14 exhibited different biological processes and signaling pathways. Inflammation, oxidative damage, apoptosis, and inflammation-related signaling pathways were enriched on POD1/12. Inflammation, chemokine activity, and downstream signaling regulated by proinflammatory cytokines, such as the MTOR signaling pathway, were enriched on POD1, while downregulation of ion channel activity, mitochondrial damage, endocytosis, MAPK and neurotrophic signaling pathways developed on POD14. Additionally, we screened key genes and candidate genes, which were verified at the transcriptional and translational levels. Our results suggest that the initiation and maintenance of HNP are regulated by different molecular mechanisms. Therefore, our research may yield a fresh and deeper understanding of the mechanisms underlying HNP, providing accurate molecular targets for HNP therapy.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  HIV; Neuropathic pain; RNA sequencing; gp120

Year:  2022        PMID: 35059976     DOI: 10.1007/s11481-021-10044-1

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  81 in total

Review 1.  PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain.

Authors:  Shu-Ping Chen; Ya-Qun Zhou; Dai-Qiang Liu; Wen Zhang; Anne Manyande; Xue-Hai Guan; Yu-Ke Tian; Da-Wei Ye; Deeq Mohamed Omar
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 2.  Mitotoxicity in distal symmetrical sensory peripheral neuropathies.

Authors:  Gary J Bennett; Timothy Doyle; Daniela Salvemini
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

3.  VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells.

Authors:  Gaia Botteri; Marta Montori; Anna Gumà; Javier Pizarro; Lídia Cedó; Joan Carles Escolà-Gil; Diana Li; Emma Barroso; Xavier Palomer; Alison B Kohan; Manuel Vázquez-Carrera
Journal:  Diabetologia       Date:  2017-08-23       Impact factor: 10.122

4.  Transcriptome analysis of dorsal root ganglia's diabetic neuropathy reveals mechanisms involved in pain and regeneration.

Authors:  Maria Carolina Pedro Athie; Andre Schwambach Vieira; Juliana Maia Teixeira; Gilson Gonçalves Dos Santos; Elayne Vieira Dias; Claudia Herrera Tambeli; Cesar Renato Sartori; Carlos A Parada
Journal:  Life Sci       Date:  2018-05-09       Impact factor: 5.037

Review 5.  Cellular and molecular mechanisms of pain.

Authors:  Allan I Basbaum; Diana M Bautista; Grégory Scherrer; David Julius
Journal:  Cell       Date:  2009-10-16       Impact factor: 41.582

6.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

7.  Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury.

Authors:  W Marie Campana; Xiaoqing Li; Veronica I Shubayev; Mila Angert; Karen Cai; Robert R Myers
Journal:  Eur J Neurosci       Date:  2006-02       Impact factor: 3.386

8.  UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the NMDA receptor antagonist MK-801.

Authors:  Jesper T Andreasen; Anders Bach; Mikko Gynther; Arafat Nasser; Jesper Mogensen; Kristian Strømgaard; Darryl S Pickering
Journal:  Neuropharmacology       Date:  2012-11-20       Impact factor: 5.250

9.  Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy.

Authors:  Sonia K Bhangoo; Matthew S Ripsch; David J Buchanan; Richard J Miller; Fletcher A White
Journal:  Mol Pain       Date:  2009-08-12       Impact factor: 3.395

10.  Peripheral nerve injury is accompanied by chronic transcriptome-wide changes in the mouse prefrontal cortex.

Authors:  Sebastian Alvarado; Maral Tajerian; Magali Millecamps; Mathew Suderman; Laura S Stone; Moshe Szyf
Journal:  Mol Pain       Date:  2013-04-18       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.